Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,509 Million (Small Cap)
33.00
NA
1.45%
-0.10
10.17%
3.29
Revenue and Profits:
Net Sales:
166 Million
(Quarterly Results - Sep 2025)
Net Profit:
38 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
26.78%
0%
26.78%
6 Months
5.54%
0%
5.54%
1 Year
31.27%
0%
31.27%
2 Years
144.16%
0%
144.16%
3 Years
-15.17%
0%
-15.17%
4 Years
-19.71%
0%
-19.71%
5 Years
-45.58%
0%
-45.58%
Shanghai Aladdin Biochemical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
22.34%
EBIT Growth (5y)
37.31%
EBIT to Interest (avg)
81.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.33
Tax Ratio
9.80%
Dividend Payout Ratio
55.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.10%
ROE (avg)
9.56%
Valuation key factors
Factor
Value
P/E Ratio
33
Industry P/E
Price to Book Value
3.27
EV to EBIT
27.27
EV to EBITDA
21.22
EV to Capital Employed
3.13
EV to Sales
6.14
PEG Ratio
NA
Dividend Yield
1.50%
ROCE (Latest)
11.47%
ROE (Latest)
9.77%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
166.40
139.10
19.63%
Operating Profit (PBDIT) excl Other Income
44.30
44.00
0.68%
Interest
3.50
1.00
250.00%
Exceptional Items
0.10
0.10
Consolidate Net Profit
38.50
31.20
23.40%
Operating Profit Margin (Excl OI)
266.10%
254.30%
1.18%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 19.63% vs 42.96% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 23.40% vs 31.09% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
529.70
402.30
31.67%
Operating Profit (PBDIT) excl Other Income
170.30
118.20
44.08%
Interest
8.40
7.30
15.07%
Exceptional Items
0.40
1.40
-71.43%
Consolidate Net Profit
115.70
85.80
34.85%
Operating Profit Margin (Excl OI)
242.20%
229.10%
1.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 31.67% vs 6.82% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 34.85% vs -7.54% in Dec 2023
About Shanghai Aladdin Biochemical Technology Co., Ltd. 
Shanghai Aladdin Biochemical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






